Sleep Apnea Diagnosis 2026: Tests, Costs, and What Your Numbers Actually Mean

Sleep apnea diagnosis in 2026: the European pathway

Sleep apnea diagnosis in 2026 is a layered process. It starts with a self-screener, moves to a home or lab sleep study, and ends with a scored report your sleep specialist uses to plan treatment. In Europe the pathway runs through your GP (medecin traitant in France, Hausarzt in Germany), then a pneumologue, Schlafmediziner, or otolaryngologist who orders the right test for your risk profile. Telehealth services now compress the journey from months to weeks, even in public systems.

This pillar walks you through every step. You will learn the three validated questionnaires that screen risk before any device is touched. You will see how a home sleep apnea test (HSAT) compares to in-lab polysomnography (PSG) for accuracy, comfort, and cost. You will read what AHI, RDI, ODI, and SpO2 mean in plain language, plus how 2026 EU diagnostic criteria changed after the European Respiratory Society (ERS) consensus update. Use the diagnosis decision tree at the end if you are unsure where to start. For deeper background, see our obstructive sleep apnea overview.

Why diagnosis matters more than self-treating

Untreated obstructive sleep apnea (OSA) raises stroke risk by 2.4x, heart attack by 1.6x, and traffic accident risk by up to 7x according to the European Society of Cardiology 2024 statement. Self-medicating with mouth tape, throat sprays, or generic stents may improve snoring but masks underlying severe OSA. A scored sleep study gives you a diagnosis with measurable severity. That is the only way to qualify for CPAP or mandibular advancement device (MAD) reimbursement in EU public systems, and the only way to know if you can use a non-prescription option like a nasal stent safely.

Step 1: Self-screening with validated questionnaires

Before any device, your doctor will ask you to complete one or more validated screeners. Three are used across the EU in 2026: the Epworth Sleepiness Scale, STOP-BANG, and the Berlin Questionnaire. Each takes under 5 minutes. None replace a sleep study, but together they decide whether you proceed to HSAT or directly to lab PSG.

The Epworth Sleepiness Scale (ESS)

The Epworth Sleepiness Scale is the most widely used daytime sleepiness questionnaire worldwide. It was developed at the Royal Prince Alfred Hospital in Sydney in 1991 and is now standard in every EU sleep clinic. You rate your chance of dozing in 8 ordinary situations on a scale of 0 (would never doze) to 3 (high chance of dozing). The 8 situations include reading, watching television, sitting in a car as a passenger for an hour, and sitting and talking to someone.

Score interpretation:

• 0 to 7: Normal daytime alertness.
• 8 to 9: Average daytime sleepiness.
• 10 to 15: Excessive daytime sleepiness, evaluation recommended.
• 16 to 24: Severe excessive daytime sleepiness, urgent referral.

An ESS score of 11 or higher is the standard threshold for sleep evaluation in NICE NG202 (UK) and HAS guidance (France).

STOP-BANG: the surgical and primary-care screener

STOP-BANG is an 8-item yes/no questionnaire developed at the University of Toronto in 2008 and validated extensively in European cohorts. It is used heavily in pre-surgical anesthesia screening across EU hospitals because anesthesia carries higher risk in undiagnosed OSA. The 8 items spell its name:

• S - Snore loudly
• T - Tired during the day
• O - Observed apneas
• P - Pressure (high blood pressure)
• B - BMI over 35
• A - Age over 50
• N - Neck circumference over 40 cm
• G - Gender male

Scoring: 0-2 low risk, 3-4 intermediate risk, 5-8 high risk. A 2024 meta-analysis in Sleep Medicine Reviews found STOP-BANG has 93% sensitivity for moderate-to-severe OSA at a cutoff of 3.

Berlin Questionnaire

The Berlin Questionnaire was developed at a 1996 Berlin conference and remains popular in German and Italian primary care. It groups 10 items into 3 categories: snoring/witnessed apnea, daytime sleepiness, and hypertension/obesity. Two or more positive categories indicate high risk. A 2023 Italian cohort published in Sleep and Breathing found Berlin caught 86% of moderate OSA cases compared to 74% for ESS alone.

Step 2: HSAT vs PSG - which sleep study is right for you

The two main test types in 2026 EU practice are home sleep apnea test (HSAT) and in-lab polysomnography (PSG). They differ in cost, sensor count, comfort, and diagnostic ceiling. Most adults with a high pre-test probability of moderate-to-severe OSA should start with HSAT. Lab PSG is reserved for complex cases or HSAT non-diagnostic results.

Home sleep apnea test (HSAT)

An HSAT (also called Type II, III, or IV polygraphy depending on channel count) is a small device you wear at home for one night. Type III is the most common in 2026 EU public clinics. It records oxygen saturation, nasal airflow, respiratory effort via thoracic and abdominal belts, and pulse rate. Some 2026 devices also record actigraphy and snoring sound. The European Respiratory Society endorses Type III HSAT for adults with high suspicion of OSA and no major comorbidities.

Strengths:

• Sleep in your own bed, on your normal schedule.
• 1 night of recording is usually sufficient.
• Costs 150 to 350 EUR private. Often free or cofunded in public systems.
• Results in 7 to 14 days from EU telehealth providers.

Limitations:

• Cannot diagnose central sleep apnea reliably.
• Misses sleep stage data (no EEG).
• False-negative rate around 10% in mild cases.
• Patient-applied sensors can fall off, requiring a redo.

In-lab polysomnography (PSG)

Lab PSG is the diagnostic gold standard. You sleep one or two nights at a hospital sleep unit (CHU sleep lab in France, Schlaflabor in Germany, Unidad del Sueno in Spain). A trained technician applies 22+ sensors including EEG (sleep stages), EOG (eye movements), EMG (muscle tone), ECG, nasal/oral airflow, thoracic and abdominal effort, oxygen saturation, body position, and limb movements. The result is a polysomnogram showing every sleep stage, every breathing event, and every arousal across the night.

PSG is mandatory in EU practice for:

• Suspected central or mixed apnea
• Significant comorbidities (severe heart failure, neuromuscular disease)
• HSAT non-diagnostic with persistent symptoms
• UARS (Upper Airway Resistance Syndrome)
• Pediatric cases (always lab-based)
• Pre-surgical assessment for sleep surgery (UPPP, MMA, Inspire/Genio)

For a deeper comparison, read our home vs lab sleep test guide.

Step 3: What your numbers actually mean

Your sleep study report contains four numbers that decide your treatment. Understanding what each one represents lets you challenge or accept your diagnosis with confidence. The four metrics are AHI, RDI, ODI, and minimum SpO2.

AHI - Apnea-Hypopnea Index

AHI is the headline number. It counts the average number of complete (apnea) and partial (hypopnea) breathing events per hour of sleep. An apnea is a 90% airflow drop lasting at least 10 seconds. A hypopnea is a 30% airflow drop with a 3% oxygen drop or arousal, per the 2024 AASM Manual revision adopted by ERS.

An AHI of 7 means you stop or shrink breathing 7 times per hour. Across an 8-hour night that is 56 events. For deeper context see understanding AHI scores.

RDI - Respiratory Disturbance Index

RDI extends AHI by adding RERAs (Respiratory Effort Related Arousals). RERAs are smaller breathing events that do not meet apnea or hypopnea thresholds but still wake you up. RDI catches UARS, a condition where AHI looks normal but daytime sleepiness is severe. UARS is most common in slim women and is often missed by HSAT alone. PSG is required to score RERAs.

ODI - Oxygen Desaturation Index

ODI counts the number of times per hour your blood oxygen drops by 3% or 4% from baseline. It correlates with cardiovascular damage independently of AHI. A 2023 European Heart Journal study found that an ODI over 15 doubles 10-year cardiovascular mortality even when AHI is in the mild range. Watch this number if you have hypertension or atrial fibrillation.

Minimum SpO2 (oxygen nadir)

This is the lowest oxygen saturation reached overnight. Healthy sleepers stay above 95%. A nadir below 88% for more than 5 minutes per night flags severe nocturnal hypoxemia and qualifies for supplemental oxygen review in EU pulmonology clinics. A nadir below 80% is a medical emergency-level finding requiring same-week specialist follow-up.

Step 4: EU diagnosis costs by country (2026)

Sleep apnea diagnosis costs vary widely across the EU. Public systems often deliver tests at no out-of-pocket cost when prescribed by a GP, but private wait times and copays differ by country. The table below summarizes 2026 costs for HSAT and lab PSG across the largest EU markets.

How EU public systems handle CPAP and MAD coverage

Once a sleep study confirms moderate-to-severe OSA (AHI greater than 15 or AHI 5-15 with comorbidity in most countries), EU public systems cover CPAP rental or purchase. Coverage is generous but conditional on adherence (typically 4 hours per night, 70% of nights, monitored by remote telemetry).

• France: CPAP fully covered by Securite Sociale (LPP code) with mandatory adherence reporting via remote monitoring.
• Germany: GKV reimburses CPAP and MAD with prescription. PKV often covers the full price including consumables.
• UK: NHS provides CPAP free of charge for AHI greater than 15 or AHI 5-15 with sleepiness.
• Spain: Seguridad Social provides CPAP through public hospitals; private prescriptions reimbursed via Mutua complementary insurance.
• Italy: SSN covers CPAP through ASL with regional variation in copay.
• Netherlands: Zorgverzekering covers CPAP after the annual eigen risico (roughly 385 EUR in 2026).

Step 5: Telehealth diagnosis in the EU (2026)

EU telehealth platforms now compress the diagnostic journey from months to under 2 weeks. They mail an HSAT device to your home, you record one night, ship it back, and a board-certified sleep physician reviews the data. Most platforms accept self-referral and direct-to-consumer payment, bypassing public-system wait lists.

Notable EU telehealth providers in 2026

• Onera Health (NL): wearable patch HSAT, used across Dutch and German private clinics. CE marked for adult OSA screening.
• ResMed myAir EU: screening + remote CPAP titration once diagnosis confirmed. Tightly integrated with EU pulmonology clinics.
• Withings ScanWatch / Sleep Analyzer: EU-marketed at-home screening with breathing-disturbance index. CE marked Class IIa.
• Vivisol / Linde Healthcare: homecare provider networks in DE/FR/ES handling test mailing and follow-up.
• NightOwl (Germany): minimalistic finger sensor HSAT with EU pulmonology partnerships.

Wait times typically run 7 to 14 days from order to scored report. Costs run 150-350 EUR for the test alone. Insurance reimbursement is improving but still patchy in 2026, with direct-pay being the most common route. Read our take on Apple Watch sleep detection for consumer wearable accuracy.

Step 6: Which EU specialist sees you next

Once a sleep study confirms OSA, an EU sleep specialist designs your treatment. The specialist title varies by country but the core training is similar: pulmonology, ENT, or neurology with a sleep medicine subspecialty. Below is the 2026 EU specialist landscape.

The European Sleep Research Society (ESRS) issues a pan-European Sleep Medicine certification recognized in most EU countries since 2014. ESRS Somnologist credentialing is a good marker of expertise when choosing private clinics.

Diagnosis decision tree

Use this tree if you are unsure where to start. It mirrors NICE NG202 and ERS 2024 guidance.

Diagnosis in special populations

Diagnosis is not one-size-fits-all. Three populations need adapted pathways.

Women

Women present with atypical symptoms: insomnia, anxiety, morning headaches, and unrefreshing sleep more often than loud snoring. They are 50% more likely to be misdiagnosed as having depression or insomnia, per a 2023 European Respiratory Journal study. RDI and PSG matter more for women because UARS prevalence is higher. Read our sleep apnea in women guide.

Children

Pediatric OSA is diagnosed only by lab PSG with pediatric scoring rules. Even an AHI of 1 is abnormal in children. Tonsillectomy resolves 70-80% of cases. See sleep apnea in children.

Elderly

OSA prevalence in EU adults over 65 reaches 30-40%. Diagnosis still requires HSAT or PSG, but treatment thresholds are sometimes individualized when AHI is borderline and symptoms are mild.

Frequently asked questions about sleep apnea diagnosis